MT2017-45: CAR-T Cell Therapy for Heme Malignancies
Recruiting
Masonic Cancer Center, University of Minnesota
2018-12-18
This is a phase II study of FDA-approved CAR-T products for patients with hematologic
malignancies. Patients will be assigned to Arm A and B based on age and diagnosis. Overall
remission rate, safety events and other endpoints will be calculated for Arm A and B
separately.
Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia
Recruiting
Kite Pharma
Phase 1
2023-10-02
To assess the feasibility of oral dasatinib pulses (3 consecutive days per week) during the
first month following infusion of brexucabtagene autoleucel (Tecartus) in adults with
relapsed or refractory B-cell acute lymphoblastic leukemia.
Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia
Recruiting
Stanford University
Phase 1
2023-10-02
To assess the feasibility of oral dasatinib pulses (3 consecutive days per week) during the
first month following infusion of brexucabtagene autoleucel (Tecartus) in adults with
relapsed or refractory B-cell acute lymphoblastic leukemia.
Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Recruiting
Kite, A Gilead Company
Phase 2
2023-12-26
This is a Phase 2 Study is to determine the efficacy and safety rate of B-Cell Acute
Lymphoblastic Leukemia (B-ALL) participants in remission with minimal residual disease (MRD)
after KTE-X19 CAR T-cell therapy
Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Recruiting
H. Lee Moffitt Cancer Center and Research Institute
Phase 2
2023-12-26
This is a Phase 2 Study is to determine the efficacy and safety rate of B-Cell Acute
Lymphoblastic Leukemia (B-ALL) participants in remission with minimal residual disease (MRD)
after KTE-X19 CAR T-cell therapy
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
